Targeting Solid Cancers with a Cancer-Specific Monoclonal Antibody to Surface Expressed Aberrantly O-glycosylated Proteins
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 9,17 MB, PDF-dokument
Originalsprog | Engelsk |
---|---|
Tidsskrift | Molecular Cancer Therapeutics |
Vol/bind | 22 |
Udgave nummer | 10 |
Sider (fra-til) | 1204-1214 |
Antal sider | 11 |
ISSN | 1535-7163 |
DOI | |
Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
M.K.M. Aasted reports grants from NEYE foundation during the conduct of the study; personal fees from GO therapeutics outside the submitted work. A.C. Groen reports other support from GO Therapeutics outside the submitted work; as well as reports a patent for anti–glyco-cd44 antibodies and their uses issued; and holds stock
Funding Information:
This work was supported by GO Therapeutics, the Neye Foundation, the European Commission (GlycoSkin H2020-ERC), and the Danish National Research Foundation (DNRF107), The Cancer Research Foundation, Friis Foundation, The Michelsen Foundation, The Danish Research Councils (Sapere Aude Research Leader grant; to H.H. Wandall), A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til Almene Formaal, the Lundbeck foundation.
Publisher Copyright:
© 2023 The Authors; Published by the American Association for Cancer Research.
Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk
ID: 373469022